Specifically, it remains unclear under which conditions PERK acts as a tumor suppressor versus a tumor promoter in CRC models, and how experimental variations (cell lines, stress inducers, PERK modulators) contribute to these divergent outcomes. The gene discussed is EIF2AK3; the disease is neoplasm.